Abstract
Introduction: This research delves into the complex interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and thyroid disorders. With the growing body of evidence suggesting a connection between COVID-19 infection and the onset of autoimmune thyroid diseases (AITD) and non-thyroidal illness syndrome (NTIS), this study aims to unravel the underlying mechanisms, identify risk factors, and explore the geographic prevalence of these conditions. The research addresses the critical need to understand the long-term implications of SARS-CoV-2 infection on thyroid health and its relationship with the phenomenon known as "long COVID". Summary: The study focuses on autoimmune manifestations, particularly AITDs, examining the relationship between COVID-19 and thyroid disorders such as Hashimoto's thyroiditis and Graves' disease. Subacute granulomatous thyroiditis (TGSA) induced by the virus and the persistence of thyroid symptoms beyond the acute phase of infection are explored. The importance of factors such as glandular trophism, pathophysiology, and the presence of symptoms in "long COVID" is emphasized. Materials and Methods: The research methodology is based on a comprehensive review of scientific literature, spanning studies from 2021 to 2023. Recognized databases such as NIH, PubMed, Cochrane, and Elsevier were utilized, prioritizing systematic reviews, meta-analyses, and relevant case reports. The search focused on risk factors, thyroid manifestations in COVID-19 patients. Results: The findings address the correlation between thyroid dysfunction and the severity of COVID-19, the impact of fT3 hormone as a predictor, and the relationship between thyroid disorders and "long COVID" syndrome. Results from various researchers are presented, including diagnostic methods, treatment modalities, and potential interventions. Conclusion: The thesis concludes that SARS-CoV-2 infection can trigger thyroid disorders, especially AITDs and NTIS, highlighting immune dysregulation as a central factor. Diagnostic strategies are proposed, modifiable and non-modifiable risk factors are discussed, and the importance of addressing persistent symptoms in "long COVID" is emphasized. The research significantly contributes to the understanding of this complex interaction, providing crucial insights for future investigations and clinical practice
Publisher
Salud, Ciencia y Tecnologia
Reference43 articles.
1. Yazdanpanah N, Rezaei N. Autoimmune complications of COVID‐19. J Med Virol. enero de 2022;94(1):54-62.
2. Trinh A, Nguyen KH, Nguyen D. Thyroid disease post COVID-19 infection: Report of a case with new-onset autoimmune thyroid disease [Internet]. Preprints; 2022 nov [citado 24 de octubre de 2023]. Disponible en: https://www.authorea.com/users/521512/articles/594364-thyroiddisease-post-covid-19-infectionreport-of-a-case-with-new-onsetautoimmune-thyroiddisease?commit=be4eb8158c2ed9a a64ab4ca8ac389c67a026266c
3. Brancatella A, Viola N, Santini F, Latrofa F. COVID-induced thyroid autoimmunity. Best Pract Res Clin Endocrinol Metab. marzo de; 37(2):101742.
4. Barahona San Millán R, Tantinyà Daura M, Hurtado Ganoza A, Recasens Sala M. Tiroiditis indolora en infección por SARS-CoV-2. Endocrinol Diabetes Nutr. diciembre de 2021;68(10):757-8.
5. Yoshikawa N, Arreaza G, Morita T, Mukuta T, Resetkova E, Miller N, et al. Studies of Human Peripheral Blood Mononuclear Cells (PBMC) from Patients with Subacute Thyroiditis in Severe Combined Immunodeficient (SCID) Mice: Less Production of Human Interferon Gamma than that Seen for Graves’ Disease. Horm Metab Res. septiembre de 1994;26(09):419-23.